|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 37105 |
FusionGeneSummary for TAF3_SVIL |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: TAF3_SVIL | Fusion gene ID: 37105 | Hgene | Tgene | Gene symbol | TAF3 | SVIL | Gene ID | 83860 | 6840 |
| Gene name | TATA-box binding protein associated factor 3 | supervillin | |
| Synonyms | TAF140|TAFII-140|TAFII140 | - | |
| Cytomap | 10p14 | 10p11.23 | |
| Type of gene | protein-coding | protein-coding | |
| Description | transcription initiation factor TFIID subunit 3140 kDa TATA box-binding protein-associated factorRNA polymerase II transcription factor TAFII140TAF(II)140TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 140kDaTBP-associated f | supervillinarchvillinmembrane-associated F-actin binding protein p205p205/p250 | |
| Modification date | 20180522 | 20180519 | |
| UniProtAcc | Q5VWG9 | O95425 | |
| Ensembl transtripts involved in fusion gene | ENST00000344293, | ENST00000375400, ENST00000375398, ENST00000355867, ENST00000535393, ENST00000460007, ENST00000538146, | |
| Fusion gene scores | * DoF score | 7 X 3 X 6=126 | 10 X 8 X 5=400 |
| # samples | 8 | 12 | |
| ** MAII score | log2(8/126*10)=-0.655351828612554 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(12/400*10)=-1.73696559416621 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: TAF3 [Title/Abstract] AND SVIL [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | TAF3 | GO:0000122 | negative regulation of transcription by RNA polymerase II | 18549481 |
| Hgene | TAF3 | GO:0043433 | negative regulation of DNA binding transcription factor activity | 18549481 |
| Hgene | TAF3 | GO:0051457 | maintenance of protein location in nucleus | 15870280 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | RV | SKCM | TCGA-FW-A3TV-06A | TAF3 | chr10 | 7866523 | + | SVIL | chr10 | 29858241 | - |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5CDS-5UTR | ENST00000344293 | ENST00000375400 | TAF3 | chr10 | 7866523 | + | SVIL | chr10 | 29858241 | - |
| 5CDS-5UTR | ENST00000344293 | ENST00000375398 | TAF3 | chr10 | 7866523 | + | SVIL | chr10 | 29858241 | - |
| 5CDS-5UTR | ENST00000344293 | ENST00000355867 | TAF3 | chr10 | 7866523 | + | SVIL | chr10 | 29858241 | - |
| 5CDS-intron | ENST00000344293 | ENST00000535393 | TAF3 | chr10 | 7866523 | + | SVIL | chr10 | 29858241 | - |
| 5CDS-intron | ENST00000344293 | ENST00000460007 | TAF3 | chr10 | 7866523 | + | SVIL | chr10 | 29858241 | - |
| 5CDS-intron | ENST00000344293 | ENST00000538146 | TAF3 | chr10 | 7866523 | + | SVIL | chr10 | 29858241 | - |
Top |
FusionProtFeatures for TAF3_SVIL |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| TAF3 | SVIL |
| Transcription factor TFIID is one of the general factorsrequired for accurate and regulated initiation by RNA polymeraseII. TFIID is a multimeric protein complex that plays a centralrole in mediating promoter responses to various activators andrepressors. Required in complex with TBPL2 for the differentiationof myoblasts into myocytes. The complex replaces TFIID at specificpromoters at an early stage in the differentiation process. | Isoform 1: Forms a high-affinity link between the actincytoskeleton and the membrane. Is among the first costamericproteins to assemble during myogenesis and it contributes tomyogenic membrane structure and differentiation (PubMed:12711699).Appears to be involved in myosin II assembly. May modulate myosinII regulation through MLCK during cell spreading, an initial stepin cell migration. May play a role in invadopodial function(PubMed:19109420). {ECO:0000269|PubMed:12711699,ECO:0000269|PubMed:19109420}. Isoform 2: May be involved in modulation of focaladhesions. Supervillin-mediated down-regulation of focal adhesionsinvolves binding to TRIP6. Plays a role in cytokinesis throughKIF14 interaction (By similarity). {ECO:0000250|UniProtKB:O46385}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for TAF3_SVIL |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for TAF3_SVIL |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| TAF3 | KHDRBS2, TAF10, TBP, TBPL2, KAT2A, TAF12, TAF13, SAP130, TAF7, CTCF, TAF5, TAF4, TAF6, TAF1, KPNA2, KPNB1, HIST3H3, HIST2H4A, MED26, NPM1, CDC23, NAP1L4, ANAPC10, CDC16, MZT1, TAF7L, TAF8, TAF11 | SVIL | LUC7L2, AR, ESR1, PPARG, NR3C1, KRT18, MIF4GD, UXT, ITGB3BP, BUB1, CENPF, FLNA, HAX1, HSP90AA1, KIFC3, LMNA, LMNB2, MPHOSPH9, NME2, ODF2, PAN3, PCNXL3, HMMR, TNFAIP1, LIMA1, ATRX, KIF14, MKL2, KMT2A, SH3PXD2A, KIF22, STARD9, SCAF4, OXCT1, VCL, COA7, PCMT1, SEPT9, NDUFV2, CFTR, TRIP6, DYNLT1, SPTBN1, SPTAN1, MYH2, CLTC, MYO1G, ACTN4, ACTN1, VIM, LYN, FLOT1, FLOT2, ACTB, GNAI1, GNB1, STOM, GPSM3, MYL12A, CALM1, GLIPR2, PAN2, HDAC8, ASB15, ASB16, USP7, CCDC8, DAPK1, LUZP4, CAPZA2, KRAS, IFI16, NINL, NIN, ADD1, CD14, CDK2, CENPE, DBN1, LLGL2, MYH9, MYH11, MYO1C, PPP1CB, PPP1CC, DNAJC7, MYH13, IQGAP1, PDLIM7, ACTR2, NES, SYNPO, MAPRE1, ANLN, MYO5C, MYO19, KLC3, MYO18A, CFAP97, CDH1, SSH1, TMOD3, TES |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for TAF3_SVIL |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for TAF3_SVIL |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Tgene | SVIL | C0023467 | Leukemia, Myelocytic, Acute | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|